Dipyridamole

Platelets

Volumn , Issue , 2007, Pages 1165-1179

  Eisert, Wolfgang G ^a,b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884771147     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369367-9/50825-9     Document Type: Chapter

References (159)

1. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
2. Diener H.C. Dipyridamole trials in stroke prevention. Neurology 1998, 51:17-19.
3. Topol E., et al. Randomized, double-blind, placebocontrolled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003, 108:399-406.
4. Diener H.C., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
5. Kaufman J., et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003, 14:2313-2321.
6. Serebruany V., et al. Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004, 75:40-47.
7. Leonardi-Bee J., et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events. Stroke 2005, 36:162-168.
8. Fitzgerald G.A. Drug therapy: Dipyridamole. N Engl J Med 1987, 316:1247-1257.
9. Gibbs C.R., Lip G.Y. Do we still need dipyridamole?. Br J Clin Pharmacol 1998, 145:323-328.
10. Stein B., Fuster V., Israel D.H., et al. Platelet inhibitor agents in cardiovascular disease: An update. J Am Coll Cardiol 1989, 14:813-836.
11. Green D., Miller V. The role of dipyridamole in the therapy of vascular disease. Geriatrics 1993, 48:46-59.
12. Blake A. Dipyridamole is neuroprotective for cultured rat embryonic cortical neurons. Biochem Biophys Res Commun 2004, 314:501-504.
13. Figueredo V.M., et al. Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury. Am J Physiol 1999, 277:H2091-H2097. (Heart Circ Physiol46) ,.
14. Kitakaze M., Minamino T., Node K., et al. Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovasc Drug Ther 1998, 12:307-309.
15. Taniguchi M., et al. Dipyridamole protects the liver against warm ischemia and reperfusion injury. J Am Coll Surg 2004, 198:758-769.
16. Riksen N.P., et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 2005, 78:52-59.
17. Picano E., Jagathesan R. The beneficial effects of long-term chronic oral dipyridamole therapy on coronary vasodilator reserve in patients with chronic stable angina: The PISA (Persantine in Stable Angina) -PET study. Circulation 2000, 102:707.
18. Serebruany V., et al. Magnitude and time course of platelet inhibition with Aggrenox® and aspirin in patients after ischemic stroke: The Aggrenox Versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol 2004, 499:315-324.
19. Serebruany V., et al. Dipyridamole decreases protease-activated receptor and annexin-V binding on platelets of poststroke patients with aspirin nonresponsiveness. Cerebrovasc Dis 2006, 21:98-105.
20. Bunag R.D., Douglas C.R., Imai S., et al. Influence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ Res 1964, 15:83-88.
21. Born G.V.R., Cross M.J. Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J Physiol 1963, 166:29P-30P.
22. Ohisalo J.J. Regulatory functions of adenosine. Med Biol 1987, 65:181-191.
23. Gamboa A., et al. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium. Circulation 2003, 108:2631-2635.
24. Elkeles R.S., Hampton J.R., Honour A.J., et al. Effect of a pyrimido-pyrimidine compound on platelet behaviour in vitro and in vivo. Lancet 1968, 2:751-754.
25. Olsson J.E., Brechter C., Backlund H., et al. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 1980, 11:4-9.
26. Chesebro J.H., Fuster V., Elveback L.R., et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984, 310:209-214.
27. Sullivan J.M., Harken D.E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiacvalve replacement. N Engl J Med 1971, 284:1391-1394.
28. Barnathan E.S., Schwartz J.S., Taylor L., et al. Aspirin and dipyridamole in the prevention of acute thrombosis complicating coronary angioplasty. Circulation 1987, 76:125-134.
29. Schwartz L., Bourassa G., Lespérance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988, 318:1714-1719.
30. White C.W., Knudson M., Schmidt D., et al. Neither ticlopidine nor aspirin-dipyridamole prevents restenosis post PTCA: Results from a randomized, placebo-controlled multicenter trial. Circulation 1987, 76:IV-213. (Suppl.).
31. Schwartz L., Lespérance Bourassa M.G., et al. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty. Am Heart J 1990, 119:232-236.
32. Mahler F., Do-Dai-Do Comparison of the combination of aspirin (50 mg) /dipyridamole (400 mg) with anticoagulants in secondary prevention following PTCA. Swiss Society for Internal Medicine, 60th Ann Mtg, Geneve, 12-13 Jun 1992. Schweiz Med Wochenschr 1992, 122:6. (Suppl.).
33. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy -I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308:81-106.
34. Forrester J.S., Merz Bairey C.N., Bush T.L., et al. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol 1996, 27:964-1047.
35. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983, 14:5-14.
36. American-Canadian Co-Operative Study Group. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. Stroke 1985, 16:406-415.
37. ESPS Study Group. European Stroke Prevention Study. Stroke 1990, 21:1122-1130.
38. Derendorf H., et al. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol 2005, 45:845-850.
39. Mellinger T.J., Bohorfoush J.G. Pathways and tissue distribution of dipyridamole (Persantine). Arch Int Pharmacodyn Ther 1965, 156:380-388.
40. Haslam R.J., Rosson G.M. Effects of adenosine on levels of adenosine cyclic 3', 5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol 1975, 11:528-544.
41. Klabunde R.E. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1993, 93:21-26.
42. Dresse A., Chevolet C., Delapierre D., et al. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982, 23:229-234.
43. Gresele P., Zoja C., Deckmyn H., et al. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost 1983, 50:852-856.
44. Gresele P., Arnout J., Deckmyn H., et al. Mechanism of the antiplatelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity. Thromb Haemost 1986, 55:12-18.
45. Ferrandon P., Barcelo B., Perche J.C., et al. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol 1994, 8:446-452.
46. German D.C., Kredich N.M., Bjornsson T.D. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 1989, 45:80-84.
47. Edlund A., Siden A., Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res 1987, 45:183-190.
48. Sollevi A., Link H., Fredholm B.B. Dipyridamole treatment doubles the plasma adenosine in patients with minor stroke. Thromb Haemost 1983, 50:20.
49. Gamboa A., et al. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium. Circulation 2003, 108:2631-2635.
50. Gamboa A., et al. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke 2005, 36:2170-2175.
51. Ahn H.S., Crim W., Romano M., et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterase of rabbit aorta. Biochem Pharmacol 1989, 38:3331-3339.
52. Gillespie P.G., Beavo J.A. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol Pharmacol 1989, 36:773-781.
53. Bult H., Fret H.R.L., Jordaens F.H., et al. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 1991, 199:1-8.
54. Akaishi Y., Fukao M., Matsuno K., et al. Dipyridamole potentiates EDRF-mediated inhibition of platelet aggregation: The role of dipyridamole as a cyclic GMP phosphodiesterase inhibitor. Cardiovasc Drug Ther 1989, 3(Suppl. 2):625.
55. Sakuma I., Akaishi Y., Fukao M., et al. Dipyridamole potentiates the anti-aggregating effect of endo theliumderived relaxing factor. Thromb Res 1990, 12:87-90. (Suppl.).
56. Rand J.H., Glanville R.W., Wu X.X., et al. The significance of subendothelial von Willebrand factor. Thromb Haemost 1997, 78:434-438.
57. Bult H., Fret H.R., Jordaens F.H., et al. Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Haemost 1991, 66:343-349.
58. Vane J.R., Meade T.W. Second European Stroke Prevention Study (ESPS 2): Clinical and pharmacological implications. J Neurol Sci 1997, 145:123-125.
59. Potel G., Maulaz B., Paboeuf C., et al. Potentiation of acenocoumarol after cutaneous application of a semisynthetic heparinoid. Therapie 1989, 44:67-68.
60. Oelze M., Mollnau H., Hoffmann N., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 2000, 87:999-1005.
61. Utz A., Aktas B., Honig-Liedl P., et al. Dipyridamole effects at physiological plasma concentrations on platelets in vitro and in vivo. Naunyn-Schmiedebergs Arch Pharmacol 2001, 363:3.
62. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arteriosclr Thromb Vasc Biol 2001, 21:1712.
63. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circ Res 2005, 97:1232.
64. Liao J.K. Stroke 2006, in press.
65. Kadatz R., Diederen W. The influence of coronary-active drugs on circulation and oxygen tension of myocardium in experimental coronary insufficiency. Arztl Forsch 1967, 21:51-60.
66. Niewiarowski S., Lukasiewicz H., Nath N., et al. Inhibition of human platelet aggregation by dipyridamole and two related compounds and its modification by acid glycoproteins of human plasma. J Lab Clin Med 1975, 86:64-76.
67. Neri Serneri G., Masotti G., Poggesi L., et al. Enhanced prostacyclin production by dipyridamole in man. Eur J Pharmacol 1981, 21:9-15.
68. Blass K.E., Block H.U., Förster W., et al. Dipyridamole: A potent stimulator of prostacyclin (PGI2) biosynthesis. Br J Pharmacol 1980, 68:71-73.
69. Mehta J., Mehta P. Dipyridamole and aspirin in relation to platelet aggregation and vessel wall prostaglandin generation. J Cardiovasc Pharmacol 1982, 4:688-693.
70. Velde V.J.S., van de Bult H., Weisenberger H., et al. Dipyridamole stimulates prostacyclin production in isolated rat aortic tissue. Arch Int Pharmacodyn Ther 1982, 256:327-328.
71. Neri Serneri G.G., Masotti G., Poggesi L., et al. Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol 1981, 21:9-15.
72. Costantini V., Talpacci A., Bastiano M.L., et al. Increased prostacyclin production from human veins by dipyridamole: An in vitro and ex vivo study. Biomed Biochim Acta 1990, 49:263-271.
73. Marnett L.J., Siedlik P.H., Ochs R.C., et al. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol 1984, 26:328-335.
74. Iuliano L., Pedersen J.Z., Rotilio G., et al. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 1995, 18:239-247.
75. Parthasarathy S., Steinberg D., Witztum J.L. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med 1992, 43:219-225.
76. Morisaki N., Stitts J.M., Bartels-Tomei L., et al. Dipyridamole: An antioxidant that promotes the proliferation of aorta smooth muscle cells. Artery 1982, 11:88-107.
77. Esterbauer H., Gebicki J., Puhl H., et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992, 13:341-390.
78. Sparrow C.P., Doebber T.W., Olszewski J., et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N-diphenyl-phenylenediamine. J Clin Invest 1992, 89:1885-1891.
79. Kuzuya M., Kuzuya F. Probucol as an antioxidant and antiatherogenic drug. Free Radic Biol Med 1993, 14:67-77.
80. Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: Sep-tember 5-6, 1991, Bethesda, Maryland. Circulation 1992, 85:2337-2344.
81. Willson R.L. Organic peroxy free radicals as ultimate agents in oxygen toxicity. Oxidative stress 1985, 41-72. Academic Press, London. H. Seis (Ed.).
82. Cruz J.P., de la Ortega G., Sanchez de la Cuesta F. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity. Biochem Pharmacol 1994, 47:209-215.
83. Cronstein B.N., Kramer S.B., Weissmann G., et al. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983, 158:1160-1177.
84. Iuliano L., Violi F., Ghiselli A., et al. Dipyridamole inhibits lipid peroxidation and scavenges oxygen radicals. Lipids 1989, 24:430-433.
85. Iuliano L., Pratico D., Ghiselli A., et al. Reaction of dipyridamole with the hydroxyl radical. Lipids 1992, 27:349-353.
86. Selly M.L., Czeti A.L., McGuiness J.A., et al. Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 1994, 111:91-97.
87. Iuliano L., Colavita A.R., Camastra C., et al. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol 1996, 119:1438-1446.
88. Tabak M., Borisevitch I.E. Interaction of dipyridamole with micelles of lysophosphatidylcholine and with bovine serum albumin: Fluorescence studies. Biochim Biophys Acta 1992, 1116:241-249.
89. Nepomuceno M.F., Alonso A., Pereira-Da-Silva L., et al. Inhibitory effect of dipyridamole and its derivates on lipid peroxidation in mitochondria. Free Radic Biol Med 1997, 23:1046-1054.
90. Nepumuceno M.F., de Oliveira Mamede M.E., Vaz de Macedo D., et al. Antioxidant effect of dipyridamole and its derivative RA-25 in mitochondria: Correlation of activity and location in the membrane. Biochim Biophys Acta 1999, 1418:285-294.
91. Bozzo J., Hernandez M.R., Ordinas A. Reduced red cell deformability associated with blood flow and platelet activation: Improved by dipyridamole alone or combined with aspirin. Cardiovasc Res 1995, 30:725-730.
92. Joiner C.H., Claussen W., Yasin Z., et al. Dipyridamole inhibits in vitro deoxygenation-induced cation fluxes in sickle red blood cells at membrane concentrations achievable. in vivo. Blood 1997, 90:125A. (Suppl.).
93. Wanless I.R., Belgiorno J., Huet P.M. Hepatitic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 1996, 24:855-864.
94. Nakamura K., Kojima K., Shirai M., et al. Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Eur J Clin Invest 1998, 28:877-883.
95. Nagase M., Kumagi H., Honda N. Suppression of proteinuria by dipyridamole in rats with aminonucleoside nephropathy. Renal Physiol 1984, 7:218-226.
96. De la Cruz J.P., Olveira C., Gonzales-Correa J.A., et al. Inhibition of ferrous-induced lipid peroxydation by dipyridamole, RA-642 and mopidamol in human lung tissue. Gen Pharmacol 1996, 27:855-859.
97. Chakrabarti S., et al. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther 2005, 315(2):494-500.
98. WeyrichA S., Zimmerman G.A. Platelets: Signaling cells in the immune continuum. Trends Immunol 2004, 25:489-495.
99. Lindemann S.W., Yost C.C., Denis M.M., et al. Neutrophils alter the inflammatory milieu by signaldependent translation of constitutive messenger RNAs. Proc Natl Acad Sci USA 2004, 101:7076-7081.
100. Lindemann S.W., Weyrich A.S., Zimmerman G.A. Signaling to translational control pathways: Diversity in gene regulation in inflammatory and vascular cells. Trends Cardiovasc Med 2005, 15:1-9.
101. Weyrich A.S., Denis M.M., Kuhlmann-Eyre J.R., et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005, 111:633-642.
102. Kim J.A., Tran N.D., Zhou W., et al. Dipyri damole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 2005, 115:435-438.
103. Eisert W. How to get from antiplatelet to antithrombotic treatment. Am J Ther 2001, 8:443-449.
104. Lauri D., Zanetti A., Dejama E., et al. Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to vascular subendothelium. Am J Cardiol 1986, 58:1261-1264.
105. Vlodavsky I., Fuks Z., Eisert W.G., et al. Platelet interaction with subendothelial extracellular matrix: Effects of platelet inhibitor drugs. Proceedings of the Conference on Radionuclide Labeled Cellular Blood Elements 1986, Bloomfontain, South Africa. A. Heyns (Ed.).
106. Gospodarowicz D., Vlodavsky I., Savion N. The extracellular matrix and the control of proliferation of vascular endothelial and vascular smooth muscle cells. J Supramol Struct 1980, 13:339-372.
107. Vlodavsky I., Eldor A., Hyam E., et al. Platelet interaction with the extracellular matrix produced by cultured endothelial cells: A model to study the thrombogenicity of isolated subendothelial basal lamina. Thromb Res 1982, 28:179-191.
108. Müller T.H., Rühr K., Callisen H., et al. Modulation of antithrombotic effects of cultured human endothelial cells by inhibitors of cyclooxygenase or phosphodiesterase. Thromb Haemost 1987, 58:155. [Abstract].
109. Eisert W.G., Müller T.H. Dipyridamole and aspirin show more than additive effect in acute thrombosis model. in vivo. Blood 1987, 70:370a. (Suppl.).
110. Kirchmaier C.M., Altorjay J., Bellinger O., et al. Dipyridamole inhibits platelet aggregation in the presence of endothelial cells. Vasa 1991, 20:318-321. (Suppl.).
111. Muller T.H., Su C.A., Weisenberger H., et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990, 30:179-186.
112. Eldor A., Vlodavsky I., Fuks Z., et al. Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: Studies with extracellular matrix covered with endothelial cells. Thromb Haemost 1986, 56:333-339.
113. Eisert W.G., Muller T.H. Dipyridamole -Evaluation of an established antithrombotic drug in view of modern concepts of blood cell-vessel wall interactions. Thromb Res 1990, 12:65-72. (Suppl.).
114. Eisert W.G. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 2001, 57(Suppl. 2):S20-S23.
115. Weber E., Haas T.A., Muller T.H., et al. Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: Influence of salicylate and dipyridamole treatment. Thromb Res 1990, 57:383-392.
116. Aznar-Salatti J., Bastida E., Escolar G., et al. Dipyridamole induces changes in the thrombogenic properties of extracellular matrix generated by endothelial cells in culture. Thromb Res 1991, 64:341-353.
117. Goldman M., Hall C., Dykes J., et al. Does 111indium-platelet deposition predict patency in prosthetic arterial grafts?. Br J Surg 1983, 70:635-638.
118. Sinzinger H., O'Grady J., Fitscha P. Platelet deposition on human atherosclerotic lesions is decreased by low-dose aspirin in combination with dipyridamole. J Int Med Res 1988, 16:39-43.
119. Lorenz M., Van Ryn J., Merk H., et al. Portable gamma spectrometry system for simultaneous monitoring of radiotracers in vivo using CdTE and CdZnTe radiation detectors probes. Nuclear Instruments Methods Phys Res A 1994, 353:448-452.
120. Van Ryn J., Lorenz M., Merk H., et al. The continuous accumulation of 99mTc-platelet and 123I-fibrin after balloon injury in the carotid artery of rabbits. Thromb Haemost 1993, 69:569.
121. Plate G., Stanson A.W., Hollier L.H., et al. Effect of platelet inhibitors on platelet and fibrin deposition following transluminal angioplasty of the atherosclerotic rabbit aorta. Eur J Vasc Surg 1989, 3:127-133.
122. Hasday J.D., Sitrin R.G. Dipyridamole stimulates urokinase production and suppresses procoagulant activity of rabbit alveolar macrophages: A possible mechanism of antithrombotic action. Blood 1987, 69:660-667.
123. Iomhair M.M., Lavelle S.M. Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals. Thromb Res 1996, 83(6):479-483.
124. Gerads I., Govers-Riemslag J.W.P., Tans G., et al. Prothrombin activation on membranes with anionic lipids containing phosphate, sulfate and/or carboxyl groups. Biochemistry 1990, 29:7967-7974.
125. Govers-Riemslag J.W.P., Janssen M.P., Waal R.F.A., et al. Effect of membrane fluidity and fatty acid composition on the prothrombin-converting activity of phospholipid vesicles. Biochemistry 1992, 31:10000-10008.
126. Zwaal R.F.A., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132.
127. Mann K.G., Nesheim M.E., Church W.R., et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990, 76:1-16.
128. Koppaka V., Wang J., Banerjee M., et al. Soluble phospholipids enhance factor Xa-catalyzed prothrombin activation in solution. Biochemistry 1996, 35:7482-7491.
129. Weinstein E.A., Li H., Lawson J.A., et al. Prothrombinase acceleration by oxidatively damaged phospholipids. J Biol Chem 2000, 275:22925-22930.
130. Rota S., McWilliam N.A., Baglin T.P., et al. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E. Blood 1998, 91:505-515.
131. De la Cruz J.P., García P.J., Sánchez de la Cuesta F. Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals. Thromb Res 1992, 66:277-285.
132. Picano E., Jagathesan R. The beneficial effects of long-term chronic oral dipyridamole therapy on coronary vasodilator reserve in patients with chronic stable angina: The PISA (Persantine in Stable Angina) -PET study. Circulation 2000, 102:707.
133. Picano E., Michelassi C. Chronic oral dipyridamole as a "novel" antianginal drug: The collateral hypothesis. Cardiovasc Res 1997, 33:666-670.
134. Picano E. Dipyridamole-echocardiography test: Historical background and physiologic basis. Eur Heart J 1989, 10:365-376.
135. Picano E., Abbracchio M.P. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res Bull 2000, 52 (3:75-82.
136. Clarke W.R., Uezono S., Chambers A., et al. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulmonary Pharmacol 1994, 7:81-89.
137. Mosca S.M., Gelpi R.J., Cingolani H.E. Adenosine and dipyridamole mimic the effects of ischemic preconditioning. J Mol Cell Cardiol 1994, 26:1403-1409.
138. Suzuki K., Miura T., Miki T., et al. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: Evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J Cardiovasc Pharmacol 1998, 31:1-9.
139. Heidland U.E., Heintzen M.P., Michel C.J., et al. Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: A prospectively randomized trial. Am Heart J 2000, 139:1039-1045.
140. Belardinelli R., Belardinelle L., Shryock J.C. Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischemic cardiomyopathy. Eur Heart J 2001, 22:1203-1213.
141. Camara S., de la Cruz J.P., Frutos M.A., et al. Effects of dipyridamole on the short term evolution of glomerulonephritis. Nephron 1991, 58:13-16.
142. Ueda N., Kawaguchi S., Niiomi Y., et al. Effect of dipyridamole treatment on proteinuria in pediatric renal disease. Nephron 1986, 44:174-179.
143. Zäuner I., Böhler J., Braun N., et al. Effect of aspirin and dipyridamole on proteinuria in idiopahtic membrane proliferative glomerulonephritis: A multicentre prospective clinical trial. Nephrol Dial Transplant 1994, 9:619-622.
144. Aizawa T., Suzuki S., Asawa T., et al. Dipyridamole reduces urinary albumin excretion in diabetic patients with normo-or microalbuminuria. Clin Nephrol 1990, 33:130-135.
145. Ingerman-Wojenski C.M., Silver M.J. Model system to study interaction of platelets with damaged arterial wall: II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719. Exp Mol Pathol 1988, 48:116-134.
146. Takehara K., Igarashi A., Ishibashi Y. Dipyridamole specifically decreases platelet derived growth factor release from platelets. Thromb Res 1990, 12:73-79. (Suppl.).
147. Takehara K., Grotendorst G.R., Silver R., et al. Dipyridamole decreases platelet-derived growth factor levels in human serum. Arteriosclerosis 1987, 7:152-155.
148. Singh J.P., Rothfuss K.J., Wiernicki T.R., et al. Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplasty. J Am Coll Cardiol 1994, 23:665-671.
149. Himmelfarb J., Couper L. Dipyridamole inhibits PDGF-and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int 1997, 52:1671-1677.
150. Chello M., Mastroroberto P., Malta Emanuelle Cirillo F., et al. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann Thorac Surg 1999, 67:1277-1282.
151. Theis J.G.W., Diechsel G., Marshall S. Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol 1999, 48:750-755.
152. Birk S., Petersen K.A., Kruuse C., et al. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 2005, 25:369-377.
153. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005, 95:1218-1222.
154. Diener H.-C., Darius H., Bertrand-Hardy J.M., et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001, 55:162-163.
155. Humphreys D.M., Street J., Schumacher H., et al. Dipyridamole may be used safely in patients with ischemic heart disease. Int J Clin Pract 2002, 56:121-127.
156. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2004, 126:483S-512S.
157. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
158. The ESPRIT Study groups Aspirin plus dipyridamole versers Aspirin alone after cercloral ischemia of arterial origin (ESPRIT): randomized, controlled trial. Lancet 2006, 367:1665-1673.
159. Norving B. Dipyridamole with Aspirin for secondary stroke prevention. Lancet 2006, 367:1638-1639.